| Identification | Back Directory | [Name]
Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl- | [CAS]
1613509-49-1 | [Synonyms]
Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl- | [Molecular Formula]
C22H19N3O2 | [MOL File]
1613509-49-1.mol | [Molecular Weight]
357.41 |
| Chemical Properties | Back Directory | [Boiling point ]
495.3±55.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
DMSO: 2mg/mL, clear (Warmed) | [form ]
Solid | [pka]
2.41±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
SRI-41315 is a small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. SRI-41315 induce a prolonged pause at stop codons and suppress PTCs associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity. | [Uses]
SRI-41315 induces a prolonged pause at stop codons and suppresses PTCs (premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR (cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity[1]. | [References]
[1] Sharma J, et al. A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. Nat Commun. 2021 Jul 16;12(1):4358. DOI:10.1038/s41467-021-24575-x |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|